Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €40.93 EUR
Change Today +1.31 / 3.30%
Volume 60.0
SGT On Other Exchanges
As of 10:28 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €47.34
52 Week Low
12/16/14 - €24.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEATTLE GENETICS INC (SGT)

seattle genetics inc (SGT) Related Businessweek News

No Related Businessweek News Found

seattle genetics inc (SGT) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 55 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGT) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Process Sciences ...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGT) Key Developments

Seattle Genetics, Inc. Announces Executive Changes

Seattle Genetics, Inc. hired and promoted several members to senior management team, including: Promoting Elaine Waller, PharmD, to Executive Vice President, Regulatory Affairs and Clinical Development Operations. Dr. Waller has been with Seattle Genetics since September 2008. She has led numerous successful regulatory initiatives for the company, including the recent ADCETRIS label expansion; Promoting Peter Senter, Ph.D., to Vice President, Chemistry and Senior Distinguished Fellow. Dr. Senter joined Seattle Genetics in August 1998. As an early member of the company's research organization, he has contributed significantly to Seattle Genetics' leadership position in ADCs and the innovative science behind its pipeline programs; Hiring Rachel Lenington as Vice President, Program, Portfolio and Alliance Management. Lenington previously spent five years at the Bill & Melinda Gates Foundation focused on global health strategies, product development and alliances. Before that she spent 10 years at Amgen; Hiring Matt Skelton as Vice President, Marketing. Skelton previously spent 16 years at Amgen in a range of sales and marketing roles. Before that, he was at Eli Lilly; Promoting Phil Tsai, Ph.D., to Vice President, Process Sciences. Dr. Tsai has been at Seattle Genetics since January 2003. During his tenure, he has led the development of many antibody and ADC manufacturing processes at various stages of the product development life cycle.

Seattle Genetics Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revises Revenue Guidance for the Full Year of 2015

Seattle Genetics reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported total revenue of $84,072,000 against $75,853,000 a year ago. Loss from operations was $26,500,000 against $15,625,000 a year ago. Net loss was $26,438,000 against $15,566,000 a year ago. Basic and diluted net loss per share was $0.21 against $0.13 a year ago. For the nine months, the company reported total revenue of $163,040,000 against $131,707,000 a year ago. Loss from operations was $995,806,000 against $49,639,000 a year ago. Net loss was $95,630,000 against $49,457,000 a year ago. Basic and diluted net loss per share was $0.76 against $0.40 a year ago. The company anticipates that 2015 revenues from ADCETRIS net product sales in the U.S. and Canada will be higher than previously anticipated, and are now expected to be in the range of $218 million to $223 million.

Seattle Genetics, Inc. Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Seattle Genetics, Inc. announced the initiation of a randomized phase 2 clinical trial of denintuzumab mafodotin (SGN-CD19A) in combination with the second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common type of aggressive non-Hodgkin lymphoma. The study is intended to evaluate the activity and safety of the combination regimen compared to RICE alone. Denintuzumab mafodotin is an antibody-drug conjugate (ADC) targeting CD19, a protein expressed uniformly on almost all B-cell malignancies. The ADC is designed to be stable in the bloodstream and release its cytotoxic agent upon internalization into CD19-expressing cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects associated with traditional chemotherapy while enhancing antitumor activity. In this phase 2 randomized, open-label, multi-center clinical trial, approximately 150 relapsed/refractory DLBCL or grade 3B follicular lymphoma patients who are eligible for an autologous stem cell transplant (ASCT) will be randomized to receive RICE either with or without denintuzumab mafodotin every three weeks for three cycles. The primary endpoint is to compare the complete remission rates between the two study arms. Secondary endpoints include safety of the combination regimen, progression-free survival, overall survival and the number of patients who are able to undergo autologous transplant.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGT:GR €40.93 EUR +1.31

SGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr892.50 DKK +17.00
Insys Therapeutics Inc $31.11 USD -1.71
Medivation Inc $41.68 USD +0.51
MorphoSys AG €56.46 EUR +0.22
Pfizer Ltd/India 2,480 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.4x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SEATTLE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at